SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change? [0.03%]
免疫抑制患者接种新冠病毒疫苗：我们需要改变策略吗？
James L Alexander,Nick Powell;British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group
James L Alexander
Silvio Danese,Tommaso Lorenzo Parigi,Laurent Peyrin-Biroulet et al.
Silvio Danese et al.
Breaking the therapeutic ceiling in drug development in ulcerative colitis [0.03%]
突破溃疡性结肠炎药物研发的治疗瓶颈
Dahham Alsoud,Bram Verstockt,Claudio Fiocchi et al.
Dahham Alsoud et al.
Increased knowledge of the intricate pathogenesis of ulcerative colitis has triggered an advance in drug development during the past two decades, resulting in the advent of several biological agents and small-molecule therapies. Although th...
Enterobius vermicularis infection associated with positive faecal occult blood testing and eosinophilia [0.03%]
肠炎钩虫感染与大便隐血阳性及嗜酸性粒细胞增多的关系
Christopher A Lamb,Daniel Parkinson,David Nylander et al.
Christopher A Lamb et al.
Serhiy Semenov,Mohd Syafiq Ismail,Deirdre McNamara
Serhiy Semenov
Luigi Laghi,Michela Cameletti,Clarissa Ferrari et al.
Luigi Laghi et al.
Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA [0.03%]
美国非酒精性脂肪肝病的种族和民族差异
Nicole E Rich,Mazen Noureddin,Fasiha Kanwal et al.
Nicole E Rich et al.
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma [0.03%]
乙型肝炎病毒相关肝细胞癌的血管内皮生长因子受体2靶向治疗研究进展
David J Pinato,Nicola Valeri,Ambreen Muhammed et al.
David J Pinato et al.